Latest Earnings Results: Q1 '26
Estimated EPS
$0.30
Reported EPS
$0.29
Surprise
-4.27%
Estimated Rev
$151.77M
Reported Rev
$156.62M
Surprise
+3.19%
• Reported GAAP EPS of $0.13 down -53.57% YoY • Reported revenue of $156.62M up 7.34% YoY • Doximity provides guidance for the fiscal second quarter ending September 30, 2026, with revenue between $170 million and $171 million and adjusted EBITDA between $80.5 million and $81.5 million for Doximity.
Bullish Takeaway
Doximity delivered revenue growth of 7% year-over-year and achieved record platform engagement, supported by strong performance from the company's AI-powered clinical tools and increased active prescriber growth.
Bearish Takeaway
Doximity experienced a significant year-over-year decline in profitability, with net income, adjusted EBITDA, and operating cash flow all decreasing compared to the prior year period for the company.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | $0.37 | -- | -- | N/A |
Q1 '26 | $0.30 | $0.29 | -4.27% | MISSED |
Q4 '25 | $0.28 | $0.26 | -8.21% | MISSED |
Q3 '25 | $0.45 | $0.46 | 2.81% | BEAT |
Q2 '25 | $0.38 | $0.45 | 18.81% | BEAT |